Abstract:Proteins of the bromodomain and extra-terminal (BET) domain family are epigenetic readers that bind acetylated histones through their bromodomains to regulate gene transcription. Dual-bromodomain BET inhibitors (DbBi) that bind with similar affinities to the first (BD1) and second (BD2) bromodomains of BRD2, BRD3, BRD4 and BRDt have displayed modest clinical activity in monotherapy cancer trials. A reduced number of thrombocytes in the blood (thrombocytopenia) as well as symptoms of gastrointestinal toxicity are dose-limiting adverse events for some types of DbBi<a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="#ref-CR3">3</a>,<a href="#ref-CR4">4</a>,<a href="/articles/s41586-020-1930-8#ref-CR5">5</a>. Given that similar haematological and gastrointestinal defects were observed after genetic silencing of Brd4 in mice<a href="/articles/s41586-020-1930-8#ref-CR6">6</a>, the platelet and gastrointestinal toxicities may represent on-target activities associated with BET inhibition. The two individual bromodomains in BET family proteins may have distinct functions<a href="#ref-CR7">7</a>,<a href="#ref-CR8">8</a>,<a href="/articles/s41586-020-1930-8#ref-CR9">9</a> and different cellular phenotypes after pharmacological inhibition of one or both bromodomains have been reported<a href="/articles/s41586-020-1930-8#ref-CR10">10</a>,<a href="/articles/s41586-020-1930-8#ref-CR11">11</a>, suggesting that selectively targeting one of the bromodomains may result in a different efficacy and tolerability profile compared with DbBi. Available compounds that are selective to individual domains lack sufficient potency and the pharmacokinetics properties that are required for in vivo efficacy and tolerability assessment<a href="#ref-CR10">10</a>,<a href="#ref-CR11">11</a>,<a href="#ref-CR12">12</a>,<a href="/articles/s41586-020-1930-8#ref-CR13">13</a>. Here we carried out a medicinal chemistry campaign that led to the discovery of ABBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-075<a href="/articles/s41586-020-1930-8#ref-CR14">14</a>. Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.

Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.

Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics

Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases

BET Bromodomain inhibitors and degraders based on polypharmacology:research advances

Small-molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic Potential.

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Disrupting Acetyl-lysine Interactions: Recent advance in the development of BET inhibitors.

Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors.

Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain

BET Inhibitors: an Updated Patent Review (2018–2021)

Successes and challenges in the development of BD1-selective BET inhibitors: a patent review

Selective inhibition of BET bromodomains

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Drug Discovery Targeting Bromodomain-Containing Protein 4

Discovery of Novel Small Molecule Induced Selective Degradation of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD4 and BRD2 with Cellular Potencies.

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy